Last edition
News about "social anxiety disorder "
AtaiBeckley Completes Patient Dosing in Phase 2b Trial of VLS-01 for Treatment-Resistant Depression
AtaiBeckley has completed dosing the final patient in its Phase 2b Elumina trial evaluating VLS-01 for treatment-resistant depression. The company expects topline results in the fourth quarter of 2026 and plans to expand the therapy into major depressive disorder and generalized anxiety disorder, subject to positive clinical outcomes.
Social Anxiety Disorder | 07/07/2026 | By News Bureau
Alembic Pharmaceuticals Secures US FDA Approval for Paroxetine ER Tablets
U.S. Food and Drug Administration grants final approval to Alembic’s sANDA for paroxetine extended-release tablets, used in treating depression and anxiety-related disorders.
Social Anxiety Disorder | 30/03/2026 | By News Bureau | 135
PharmAla Biotech Australia Ties Up with UK CDMO to Manufacture ALA-002
PharmAla Biotech Australia has contracted a UK-based CDMO to manufacture the drug substance for ALA-002, its patented non-racemic MDMA formulation, ahead of planned phase 2a/2b clinical trials for social anxiety disorder expected to begin in 2026.
Social Anxiety Disorder | 16/12/2025 | By News Bureau | 255
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy